PV Bulletin

Revised Draft Product-Specific Guidances for Generic Peptide Products

The FDA issued 17 revised draft guidances to update regulations surrounding generic peptide drugs, emphasizing impurity and immunogenicity assessments.

Primary source: Center for Drug Evaluation and Research 2026 Guidance Agenda

PV Impact Brief

Urgency: HighConfidence: high

What changed

Mandatory updates to purity characterization and immunogenicity assessment protocols for generic peptide products outlined in the 17 revised PSGs, effective from the published date.

Why it matters

These changes reflect an essential evolution in the FDA's approach, potentially leading to increased safety and efficacy of generic peptide medications, which are critical for conditions like diabetes and osteoporosis.

Action needed

Sponsors and clinical safety teams must revise and enhance their protocols for impurity analysis and immunogenicity assessments in alignment with the newly released guidances, ensuring all future ANDAs meet updated safety criteria.

Relevant for
Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Draft Guidance
Policy status
revised
Publication date
2026-07-28
Policy change
The FDA has issued 17 revised draft product-specific guidances (PSGs) for peptide drug products, originally published in May 2021, to refine the scientific and regulatory approach for generic peptide drug assessment. These guidances provide recommendations for applicants submitting abbreviated new drug applications (ANDAs) to ensure generic versions are bioequivalent and safe. The revisions specifically address the identification and comparative analysis of impurities and the assessment of immunogenicity risk relative to the reference listed drug.

Key changes

Inclusion of recommendations for impurity profile analysis in ANDA submissions; requirement for a comparative analysis of impurity and immunogenicity profiles between the generic and reference drug; updates to scientific standards for 17 specific peptide products including Calcitonin salmon and Dasiglucagon.

Affected workflows

Signal Management

Responsible groups

SponsorsClinical SafetyRegulatory AffairsPharmacovigilance Operations

Document identifiers

FDA-2007-D-0369

PV impact

Sponsors and clinical safety teams developing generic peptides must update their impurity characterization and immunogenicity assessment protocols. The emphasis on immunogenicity risk assessment means that post-marketing safety monitoring strategies may need to be more robust for products with identified impurity differences. Clinical safety departments should review the 17 specific guidances to ensure that ongoing or planned bioequivalence studies meet the updated safety characterization criteria.

View regulator source

Source document details

Exact policy details

Published Date of Revised Draft PSGs
2026-07-28
Applies to: Applicable to generic peptide drug assessments.
Published date indicating when the 17 revised draft PSGs for peptide products were made available. · p. 1 · High · Source
Total Number of Revised Draft PSGs
17
Applies to: Pertains to the revised draft PSGs addressing specific peptide products.
The document mentions 'Today, the Food and Drug Administration published 17 revised draft product-specific guidances (PSGs) for peptide products'. · p. 1 · High · Source
Areas of Updated Recommendations
Submission methods, innate immune response testing, impurity thresholds, higher order structure assessment, biological activity assessment.
Applies to: Guidance for the development of generic peptide drug products.
The document outlines the key areas addressed in the revised draft PSGs. · p. 1 · High · Source
Comment Submission Before Finalization
All comments are considered before finalizing PSGs.
Applies to: Applicable to stakeholders interested in the PSGs.
FDA considers all comments submitted to the public docket before finalizing PSGs. · p. 1 · High · Source

Extracted documents

Unable to extract linked source document: https://www.hhs.gov/vulnerability-disclosure-policy/index.html

Evidence and confidence

Confidence: highSource updated: Jul 28, 2026

Full briefing

Practical implication

Sponsors and clinical safety teams must revise and enhance their protocols for impurity analysis and immunogenicity assessments in alignment with the newly released guidances, ensuring all future ANDAs meet updated safety criteria.

The FDA has published 17 revised draft product-specific guidances (PSGs) for certain generic peptide products, focused on improving assessment methods for generic drug applications (ANDAs). Key updates include enhanced impurity profiling and immunogenicity risk assessment, requiring sponsors to adjust protocols accordingly to ensure compliance with current safety standards.

What changed: Mandatory updates to purity characterization and immunogenicity assessment protocols for generic peptide products outlined in the 17 revised PSGs, effective from the published date.

Why it matters: These changes reflect an essential evolution in the FDA's approach, potentially leading to increased safety and efficacy of generic peptide medications, which are critical for conditions like diabetes and osteoporosis.

Practical implication: Sponsors and clinical safety teams must revise and enhance their protocols for impurity analysis and immunogenicity assessments in alignment with the newly released guidances, ensuring all future ANDAs meet updated safety criteria.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Reporting Requirement#revised#policy-change#firecrawl-policy-agent#Food and Drug Administration (FDA)#Draft Guidance

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward